Three EU Countries Strike Landmark Joint Zolgensma Pricing Deal
Executive Summary
BeNeLuxA, the cross-country medicines access initiative, says it is now the “gold standard” for voluntary collaboration in Europe after a ground-breaking deal was reached with Novartis.
You may also be interested in...
European Countries Should Join Forces To Lower Prices of Zolgensma & Kaftrio
The Dutch HTA institute is calling for hefty discounts of 50% and 75% for Novartis’s gene therapy and Vertex’s cystic fibrosis product.
Where Europe’s ‘BeNeLuxA’ Joint Pricing Pilot May Have Gone Wrong
A more innovative approach to pricing and reimbursement arrangements is needed in the pilot BeNeLuxA joint pricing negotiations, says Eurordis head Yann Le Cam. The Netherlands and Belgium are expected to re-start the negotiations soon after a “time-out” period.
Libmeldy Gene Therapy Brings Considerable Extra Benefit, Says German Body
With talks to form a new coalition progressing in Germany, the new government, which could take office in early December, is expected to introduce measures to curb pharmaceutical spending. Orphan drugs could be among products targeted.